Table 1.
The role of interleukin-6 (IL-6) in metabolic regulation in humans.
| Subject/Description | Treatment | Observed Effects | Reference |
|---|---|---|---|
| Human/healthy males | rhIL-6 infusion for 4 h | Increase of lipolysis in skeletal muscle; Increase of systemic FA oxidation | [20] |
| Human/healthy males | IL-6 infusion for 2.5 h | Net increase of glycerol from subcutaneous adipose tissue; Increased uptake of FA and glycerol in splanchnic regions | [24] |
| Human/healthy males | IL-6 infusion for 4 h | Increased FA oxidation | [25] |
| Human/males with T2D vs. control | rhIL-6 infusion for 3 h | Increase of palmitate Ra and Rd in both groups | [26] |
| Human/healthy males | IL-6 infusion for 3 h | Increase of serum FA levels; Increased Ra of endogenous FA; Enhanced systemic FA oxidation |
[27] |
| Human/patients with multicentric Castleman disease | Treatment of humanized anti-human IL-6 receptor monoclonal antibody | Gain of body weight; Hypertriglyceridemia; Hypercholesterinemia | [28] |
| Human/healthy females with G or C alleles at position 174 of IL-6 gene | n.d. | Trend of increased plasma IL-6 levels and elevated serum TG, VLDL-C and FFA in IL-6 G174C polymorphism | [29] |
rhIL-6, Recombinant human IL-6; FA, Fatty acid; Ra, Rate of appearance; Rd, Rate of disappearance; n.d., No data; TG, Triglyceride; VLDL-C, Very-low-density lipoprotein cholesterol; FFA, Free fatty acid.